載入...
Safety and Efficacy of PD-1/PD-L1 Inhibitors in Cancer Patients With Preexisting Autoantibodies
BackgroundProgrammed cell death protein-1/programmed cell death ligand-1 (PD-1/PD-L1) inhibitors therapy is now a routine scheme in cancers. However, the effect of preexisting autoantibodies on the safety and efficacy of PD-1/PD-L1 inhibitors in cancer patients is not well understood.MethodsThe pres...
Na minha lista:
| Main Authors: | , , , , , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Frontiers Media S.A.
2022-05-01
|
| 叢編: | Frontiers in Immunology |
| 主題: | |
| 在線閱讀: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.893179/full |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|